Loading company
LivaNova PLC
LIVN · Nasdaq · ·
Next earnings: November 4, 2026 · before the open
$76.97-0.3%Sep 29 close
- 1M
- -4.0%
- 6M
- +19.1%
- 1Y
- +52.1%
- 5Y
- -7.8%
LIVN · Nasdaq · ·
Next earnings: November 4, 2026 · before the open
$76.97-0.3%Sep 29 close
LivaNova PLC is scheduled to report next on November 4, 2026, before the open. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $390.6M | $352.5M | +10.80% |
| Profit | $108.6M | $27.2M | +299.72% |
| Profit per share | $1.93 | $0.50 | +286.00% |
| Free Cash Flow | $35M | $47.8M | -26.66% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“below, the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Accordingly, the Company is unable to reconcile forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts. 1 • Appointed Jette Nygaard-Anderson to the Board of Directors and the Nominating and Corporate Governance Committee, effective June 10 • Appointed Stefano Folli as President, Cardiopulmonary, effective August 1, after joining the Company on June 1 • Appointed Anne Liddy as Chief Legal Officer, effective August 31 “In the second quarter, LivaNova delivered strong revenue growth driven by sustained performance in our Cardiopulmonary and Epilepsy businesses,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
LivaNova PLC is a global medical technology company built on nearly five decades of experience with a vision to change the trajectory of lives for a new day. Through ingenious medical solutions in select neurological and cardiac conditions, LivaNova strives to ignite patient turnarounds. With its registered office in the United Kingdom, approximately 3,300 employees, and a presence in more than 100 countries, LivaNova serves patients, healthcare professionals, and healthcare systems worldwide.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from LivaNova PLC’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
LivaNova PLC has no earnings call transcript available.